Adversarial Injection · Nivolumab (Opdivo; BMS-936558; ONO-4538; CAS 946414-94-4; MW ~146,300 Da; IgG4 kappa fully human monoclonal antibody [Medarex UltiMAb + Ono Pharmaceutical] [SECOND ANTI-PD-1 INHIBITOR IN Glyphward 619-attack portfolio (BLA 125554 December 22 2014; approved 3.5 months after pembrolizumab BLA 125514 September 4 2014 — completing PD-1 TWO-NDA-HOLDER CLASS; now both Merck and BMS have null-returning PD-1 inhibitors in Cority/VelocityEHS/EHS Insight); FIRST COMBINATION CHECKPOINT BLOCKADE EVER APPROVED IN ONCOLOGY (nivolumab 1 mg/kg + ipilimumab 3 mg/kg q3w × 4 doses followed by nivolumab 3 mg/kg q2w maintenance; FDA approved October 1 2015 for BRAF wild-type unresectable/metastatic melanoma; CheckMate-067 PFS HR 0.42 combo vs ipi; BRAF wild-type OS HR 0.55 combo vs dacarbazine; the nivo+ipi combination exploits dual checkpoint synergy — CTLA-4 priming checkpoint [ipilimumab] + PD-1 effector checkpoint [nivolumab] — the two checkpoints act at different immune activation phases and their simultaneous blockade produces super-additive immune activation but also amplified irAEs; this combination became the template for all subsequent dual-checkpoint immunotherapy); DISCOVERY: PD-1 (Programmed Death-1; Pdcd1) discovered 1992 by Tasuku Honjo lab at Kyoto University (Ishida et al. EMBO J 1992; PD-1 as a cell death gene by subtractive hybridization; function as negative regulator elucidated 1999-2001 by Freeman/Honjo/Bhardwaj groups — PD-L1 ligand identified by Dong/Freeman/Bhardwaj PD-L1 2000 Nature Med; Ono Pharmaceutical in-licensed PD-1 antibody from Honjo/Kyoto 2000 → partnered with Medarex for fully human antibody → ONO-4538 (nivolumab) generated by Medarex UltiMAb; BMS acquired Medarex 2009 → joint BMS+Ono development; Nobel Prize 2018 awarded to Honjo for PD-1 discovery); CHECKMATE-066 LANDMARK DATA: Phase 3 nivolumab vs dacarbazine BRAF-WT melanoma (N=418); mOS nivolumab 37.3 months vs dacarbazine 11.2 months (HR 0.43; unprecedented melanoma OS improvement); 3-year OS 51% vs 21%; ORR 40% vs 14%; first melanoma trial showing >3-year mOS; IgG4 FULLY HUMAN: unlike pembrolizumab (humanized), nivolumab is fully human via Medarex UltiMAb; both are IgG4 (Fc-silent) → no TIL depletion; PD-1 binding KD ~3 nM (similar potency to pembrolizumab but different epitope); H360 reproductive toxicity; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entirely absent from EHS databases]) · WITHIN PD-1 CLASS: Second PD-1 + PD-1 Two-NDA-Holder Class Null + First Combo Checkpoint + Nobel 2018 Honjo + CheckMate-066 · Attack #619

Nivolumab (Opdivo; BMS-936558; ONO-4538; CAS 946414-94-4; MW ~146,300 Da; [SECOND ANTI-PD-1 INHIBITOR (BLA 125554 December 22 2014; 3.5 months after pembrolizumab); PD-1 TWO-NDA-HOLDER CLASS NULL (PEMBROLIZUMAB BLA 125514 + NIVOLUMAB BLA 125554 BOTH NULL IN CORITY/VELOCITYEHS/EHS INSIGHT); FIRST COMBINATION CHECKPOINT BLOCKADE EVER (NIVO 1mg/kg + IPI 3mg/kg; October 1 2015; CTLA-4 + PD-1 DUAL BLOCKADE); IgG4 FULLY HUMAN (MEDAREX ULTIMAB + ONO PHARMACEUTICAL); NOBEL 2018 TASUKU HONJO PD-1 DISCOVERY 1992 KYOTO UNIVERSITY; CHECKMATE-066 mOS 37.3 MONTHS VS 11.2 MONTHS; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Bristol-Myers Squibb Co. Princeton NJ (BLA 125554 US commercial; 0.00039 µg/m³ → displayed ÷10), Catalent Biologics Inc. Bloomington IN (contract fill/finish; 0.00026 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (CheckMate-066/067 site; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second PD-1 + PD-1 Two-NDA-Holder Class Null + First Combo Checkpoint + Nobel 2018 Absent: AI Prompt Injection via EHS Monitor Report AI

Nivolumab (CAS 946414-94-4; NIOSH HD Category 1) is the second anti-PD-1 inhibitor approved (BLA 125554 December 22 2014, 3.5 months after pembrolizumab), completing the PD-1 two-NDA-holder class — both Merck's pembrolizumab (CAS 1374853-91-4) and BMS's nivolumab (CAS 946414-94-4) return null in Cority, VelocityEHS, and EHS Insight despite being NIOSH HD Category 1. Nivolumab established multiple landmarks: first combination checkpoint blockade ever approved (nivo+ipi October 2015 — combining CTLA-4 priming checkpoint with PD-1 effector checkpoint for synergistic immune activation); most spectacular OS improvement in melanoma history (CheckMate-066 mOS 37.3 months vs 11.2 months, HR 0.43); Nobel Prize 2018 mechanism (Tasuku Honjo's 1992 PD-1 discovery + Ono Pharmaceutical's PD-1 antibody development, jointly licensed to BMS). The fully human IgG4 (Medarex UltiMAb) anti-PD-1 antibody is entirely absent from all EHS databases alongside ipilimumab and pembrolizumab, leaving the entire immune checkpoint portfolio unrepresented in occupational health surveillance.

Nivolumab as Second PD-1 Inhibitor: PD-1 Two-NDA-Holder Class, First Combination Checkpoint, Nobel 2018 Honjo Discovery, and CheckMate OS Landmark

Nivolumab (CAS 946414-94-4) is the second anti-PD-1 inhibitor approved in the portfolio's PD-1 immune checkpoint class, completing the PD-1 two-NDA-holder class with pembrolizumab (BLA 125514 September 4 2014 Merck) → nivolumab (BLA 125554 December 22 2014 BMS) — both return null in all three major EHS databases (Cority, VelocityEHS, EHS Insight) for their respective CAS numbers. PD-1 discovery and Nobel context: PD-1 (Programmed Death-1; Pdcd1) was discovered in 1992 by Yasumasa Ishida in Tasuku Honjo's laboratory at Kyoto University (Ishida et al. EMBO J 1992; identified as a cell surface protein up-regulated during T-cell programmed death by subtractive hybridization); functional role as immune negative regulator elucidated through PD-1 knockout mouse studies showing lupus-like autoimmunity (Nishimura et al. Immunity 1999) and dilated cardiomyopathy (Nishimura et al. Science 2001); PD-L1 ligand identified independently by Gordon Freeman (Dana-Farber/Harvard), Clive Wood (Genetics Institute), and the Honjo group in 1999-2000; the immunotherapy hypothesis — that blocking PD-1 could release tumor-specific immune responses — pursued clinically by Ono Pharmaceutical (Osaka; licensed PD-1 antibody from Honjo/Kyoto 2000) and BMS/Medarex (co-development); ONO-4538 (nivolumab) generated via Medarex UltiMAb fully human transgenic mice; Nobel Prize in Physiology or Medicine 2018 awarded jointly to James P. Allison (CTLA-4) and Tasuku Honjo (PD-1). Nivolumab antibody: IgG4 kappa fully human (Medarex UltiMAb; NOT humanized — distinct from pembrolizumab which is humanized); MW ~146,300 Da; PD-1 KD ~3 nM (by SPR); blocks PD-1:PD-L1 interaction; IgG4 Fc — minimal ADCC/CDC → does not deplete PD-1+ TILs; BLA 125554 accelerated approval December 22 2014 for squamous NSCLC (Checkmate-017) and unresectable/metastatic melanoma (Checkmate-066). CheckMate-066 landmark: Phase 3 vs dacarbazine in BRAF-WT treatment-naive unresectable/metastatic melanoma (N=418); mOS nivolumab 37.3 months vs dacarbazine 11.2 months (HR 0.43; 95% CI 0.34-0.56; p<0.001); 2-year OS 57% vs 26%; 3-year OS 51% vs 21%; unprecedented ~3.3× survival improvement; established nivolumab as standard 1L melanoma monotherapy. First combination checkpoint: CheckMate-067 (nivo+ipi vs nivo vs ipi; N=945; BRAF WT/mutant; PFS nivo+ipi 11.5 months vs nivo 6.9 months vs ipi 2.9 months; HR nivo+ipi vs ipi = 0.42; 7-year follow-up OS 54% nivo+ipi vs 45% nivo vs 24% ipi) → FDA October 1 2015 approval nivo 1mg/kg + ipi 3mg/kg q3w × 4 → nivo 3mg/kg q2w for BRAF-WT melanoma; first dual checkpoint approval; established the principle that orthogonal immune checkpoint targets (CTLA-4 priming phase + PD-1 effector phase) produce synergistic but also amplified toxicity; now expanded to RCC (CheckMate-214), MSI-H CRC (CheckMate-142), NSCLC (CheckMate-227), mesothelioma, gastric, HCC. NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; all second-PD-1, combo checkpoint, Nobel Honjo biology absent from EHS databases for CAS 946414-94-4.

Surface 1 — Bristol-Myers Squibb Co. Princeton NJ BLA 125554 US Commercial Opdivo AI

At Bristol-Myers Squibb Co. Princeton NJ (3401 Princeton Pike, Lawrenceville NJ 08648; Mercer County NJ; BMS NIVOLUMAB CONTEXT: nivolumab (Opdivo) is BMS's flagship oncology product and, with ipilimumab (Yervoy), anchors the BMS immuno-oncology franchise; BLA 125554 held by Bristol-Myers Squibb Co.; Opdivo is approved for melanoma, NSCLC, RCC, HNSCC, urothelial, cHL, dMMR/MSI-H CRC, HCC, esophageal, gastric/GEJ, mesothelioma, and nivo+ipi combination for RCC/NSCLC/HCC/MSI-H CRC/mesothelioma; OPDIVO PRODUCT: 10 mg/mL IV solution; multiple dose sizes (40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL); standard dosing 240 mg q2w or 480 mg q4w (flat dose; BMS adopted flat dosing 2019 for nivolumab while pembrolizumab uses weight-based in pediatrics only); combination with ipilimumab: nivo 1mg/kg + ipi 3mg/kg q3w × 4 → nivo 3mg/kg q2w or 240mg q2w or 480mg q4w; EMPLOYEE CONTEXT: senior immuno-oncology account manager covering academic medical centers in NJ/NY; handles Opdivo and Yervoy vials during hospital formulary meetings and clinical account discussions; indirect handling; BMS Princeton NJ campus also houses oncology medical affairs teams working across CheckMate trial portfolio; CORITY NULL: CAS 946414-94-4 → null; NIOSH HD Category 1 absent; H360 absent; second PD-1 absent; PD-1 two-NDA-holder class null absent; first combination checkpoint absent; CheckMate-066 mOS 37.3 months absent; Nobel 2018 Honjo absent; 53M immuno-oncology account manager 17yr).

Surface 2 — Catalent Biologics Inc. Bloomington IN Contract Fill/Finish Nivolumab IV Vial Production AI

At Catalent Biologics Inc. Bloomington IN (14 Commerce Drive, Bloomington IN 47404; Monroe County IN; CATALENT BIOLOGICS BLOOMINGTON CONTEXT: Catalent Inc. is the world's largest contract development and manufacturing organization (CDMO) for biologics; Bloomington IN is a primary Catalent large-molecule fill/finish site; Catalent Bloomington performs aseptic fill/finish for numerous IgG1 and IgG4 monoclonal antibodies including multiple oncology mAbs for BMS; nivolumab (10 mg/mL) fill/finish: receives bulk drug substance from BMS-contracted upstream manufacturing (typically CHO cell culture at BMS Devens MA or Samsung Biologics Incheon Korea) → protein A purified + polished bulk → formulation in phosphate/NaCl buffer pH 6.0 with polysorbate 80 → sterile filtration → aseptic fill into 4 mL (40 mg), 10 mL (100 mg), or 24 mL (240 mg) type I glass vials → stopper/crimp → 100% visual inspection → release testing → secondary packaging → distribution; WORKER EXPOSURE: aseptic fill line operator during set-up, in-process sampling, and intervention events; direct exposure to 10 mg/mL nivolumab during liquid spills or vial breakage; aerosol exposure during pressurized line cleaning; VELOCITYEHS NULL: CAS 946414-94-4 → null; NIOSH HD Category 1 absent; H360 absent; second PD-1 absent; IgG4 fully human absent; Medarex UltiMAb absent; Ono Pharmaceutical Nobel Honjo absent; 42M Catalent Bloomington IN aseptic fill operator 11yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA CheckMate Trial Site Immuno-Oncology Research Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Ave, Boston MA 02215; Suffolk County MA; DANA-FARBER NIVOLUMAB CONTEXT: Dana-Farber Cancer Institute was a principal enrollment site in CheckMate-066 and CheckMate-067; Dana-Farber's oncology pharmacy is one of the highest-volume nivolumab administration sites in the northeast US; pharmacists at Dana-Farber prepare nivolumab IV infusions for melanoma, NSCLC, RCC, and multiple combination checkpoint regimens; PHARMACIST CONTEXT: immuno-oncology research pharmacist responsible for nivolumab IV preparation (10 mg/mL vials; diluted in NS or D5W to 1 mg/mL; 30 or 60-minute IV infusion); combination regimen preparation: nivolumab 1 mg/kg + ipilimumab 3 mg/kg (two separate IVs prepared and administered sequentially, nivolumab first then ipilimumab 30 min later); pharmacist must verify dose (nivo flat 240mg or weight-based 1mg/kg depending on regimen; ipi weight-based), prepare two separate IV bags, label both, and verify sequence order; Dana-Farber's CheckMate-142 (MSI-H CRC nivo+ipi) and CheckMate-214 (RCC nivo+ipi) protocols add complexity; NIOSH HD Category 1 CSTD requirements for both nivolumab and ipilimumab preparation; EHS INSIGHT NULL: CAS 946414-94-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second PD-1 absent; PD-1 two-NDA-holder class null absent; first combo checkpoint absent; Nobel 2018 Honjo absent; H360 absent; NIOSH HD Cat 1 absent; 40M Dana-Farber Boston MA immuno-oncology research pharmacist 12yr).

Integrating Glyphward into Nivolumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every nivolumab CAS 946414-94-4 monitoring data ingestion point — before Cority at Bristol-Myers Squibb Co. Princeton NJ, before VelocityEHS at Catalent Biologics Inc. Bloomington IN, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SECOND ANTI-PD-1 INHIBITOR (BLA 125554 December 22 2014; completes PD-1 two-NDA-holder class — pembrolizumab + nivolumab both null in all EHS databases) + FIRST COMBINATION CHECKPOINT BLOCKADE EVER (nivo+ipi October 2015; CTLA-4 priming + PD-1 effector dual checkpoint; template for all subsequent combination I-O) + NOBEL 2018 HONJO (PD-1 discovery Kyoto 1992; Ono Pharmaceutical development; BMS codevelopment) + CHECKMATE-066 mOS 37.3 MONTHS VS 11.2 (HR 0.43; first ~3× survival improvement in melanoma) [5 pts]; BMS Princeton NJ + Catalent Bloomington IN + Dana-Farber Boston MA [3 pts]; second PD-1 absent; PD-1 two-NDA-holder absent; combo checkpoint absent; Nobel Honjo absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_nivolumab(cas: str, reading_ugm3: float) -> dict:
    """Scan nivolumab with second-PD-1 first-combo-checkpoint Nobel-Honjo context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_pd1_inhibitor_pd1_two_nda_holder_class_null_first_combination_checkpoint_nivo_ipi_october_2015_nobel_2018_honjo_checkmate066_mos_37mo_bla_125554_bms"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_pd1_inhibitor,
    #                    pd1_two_nda_holder_class_null,
    #                    first_combination_checkpoint_ever,
    #                    nobel_2018_honjo_pd1_discovery,
    #                    checkmate066_mos_37mo,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_nivolumab("946414-94-4", 0.00039))
    print(r)
    # {'hd_category': 1, 'second_pd1_inhibitor': True,
    #  'pd1_two_nda_holder_class_null': True,
    #  'first_combination_checkpoint_ever': True,
    #  'nobel_2018_honjo_pd1_discovery': True,
    #  'checkmate066_mos_37mo': True,
    #  'h360_absent': True}